Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

INSIDE INDUSTRY
Novel technology from Columbia University for neurobiological research
A bcam Plc., a producer and distributor of high quality protein research tools, and Columbia University, announced that they have entered into an exclusive license agreement for two novel pH-responsive fluorescent false neurotransmitters (FFNs). FFNs are probes which act as optical tracers, allowing imaging of neurotransmitter release from individual presynaptic terminals in the brain. Under the terms of the agreement, Abcam Biochemicals will provide the FFN compounds to its customers as part of the Abcam Biochemicals range, to support both fundamental and applied neurobiological research, including neurodegeneration and drug addiction.

The two FFNs licenced by Abcam are FFN102 and FFN202, which are first-of-a-kind small molecules that act as pH sensors. FFN102, which allows measurement of activity at dopamine synapses, enables the further study of synaptic plasticity by allowing optical imaging of dopaminergic presynaptic terminals. FFN202 may be used to screen drugs and other molecules to examine their effects on the pH of secretory vesicles.

Both FFN102 and FFN202 are sufficiently bright, photostable and suitable for two-photon and standard fluorescence microscopy and are compatible with GFP tags.

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.